CLINICAL_TRIALS ClinicalTrials.gov record update

Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy (PDR).

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01281098
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:58.215924+00:00
Published At: 2015-03-19T00:00:00+00:00
Record Updated At: 2015-03-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["High Risk Proliferative Diabetic Retinopathy", "Diabetes Mellitus Type I", "Diabetes Mellitus Type II"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2015-03-19"
protocolSection.identificationModule.nctId: "NCT01281098"
protocolSection.identificationModule.officialTitle: "Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen\u00ae (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy (PDR)."
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.